Kanjinti 420 mg

KANJINTI 420 MG is a pharmaceutical product containing trastuzumab, used for targeted therapy. This intravenous kit is manufactured by Amgen Canada Inc. and is designed for specific medical applications.

KANJINTI 420 MG, containing trastuzumab, is primarily used in the treatment of certain types of cancer. It is often prescribed for conditions where targeted therapy is beneficial, such as in the management of HER2-positive breast cancer. Patients may wonder, 'What is KANJINTI 420 MG used for?' and the answer lies in its role as a monoclonal antibody that targets specific proteins involved in cancer cell growth.

Common effects of KANJINTI 420 MG may include infusion reactions, fatigue, and nausea. Some patients might experience fever, chills, or weakness. These effects can vary from person to person and are not exhaustive. Always consult a healthcare provider for personalized information.

KANJINTI 420 MG should be handled with care and administered by a healthcare professional. It is important to follow the prescribed guidelines for storage and administration. Patients with known allergies to trastuzumab or any of the kit's components should inform their healthcare provider before use.

KANJINTI 420 MG may interact with other medications, including those that affect the immune system. It is crucial to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always follow the advice of a healthcare professional regarding the use of this product.